Alopecia areata during Interferon Alpha-2b/Ribavirin Therapy (2002)

Letters| October 21 2002 Alopecia areata during Interferon Alpha-2b/Ribavirin Therapy Subject Area: Dermatology , Immunology and Allergy N. Agesta; N. Agesta Department of Dermatology, Cruces University Hospital, Barakaldo-Bilbao, Spain Search for other works by this author on: This Site PubMed Google Scholar R. Zabala; R. Zabala Department of Dermatology, Cruces University Hospital, Barakaldo-Bilbao, Spain Search for other works by this author on: This Site PubMed Google Scholar J.L. Díaz-Pérez J.L. Díaz-Pérez Department of Dermatology, Cruces University Hospital, Barakaldo-Bilbao, Spain Search for other works by this author on: This Site PubMed Google Scholar Dermatology (2002) 205 (3): 300–301. https://doi.org/10.1159/000065841 Article history Published Online: October 21 2002 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation N. Agesta, R. Zabala, J.L. Díaz-Pérez; Alopecia areata during Interferon Alpha-2b/Ribavirin Therapy. Dermatology 1 July 2002; 205 (3): 300–301. https://doi.org/10.1159/000065841 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsDermatology Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 2002Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.